Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Capricor Therapeutics (CAPR) over the last 9 years, with Q3 2025 value amounting to $45.7 million.

  • Capricor Therapeutics' Shares Outstanding (Diluted Average) rose 3815.67% to $45.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.7 million, marking a year-over-year increase of 3815.67%. This contributed to the annual value of $35.2 million for FY2024, which is 3151.9% up from last year.
  • As of Q3 2025, Capricor Therapeutics' Shares Outstanding (Diluted Average) stood at $45.7 million, which was up 3815.67% from $45.7 million recorded in Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' Shares Outstanding (Diluted Average) peaked at $45.7 million during Q3 2025, and registered a low of $22.2 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $25.3 million (2023), whereas its average is $29.5 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 5263.93% in 2021, then surged by 397.24% in 2023.
  • Capricor Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $23.1 million in 2021, then rose by 6.34% to $24.6 million in 2022, then increased by 9.06% to $26.8 million in 2023, then soared by 31.52% to $35.2 million in 2024, then increased by 29.81% to $45.7 million in 2025.
  • Its last three reported values are $45.7 million in Q3 2025, $45.7 million for Q2 2025, and $45.6 million during Q1 2025.